Recruiting

Testing a new treatment to slow thinking and memory decline

Plain-English translation of NCT07589595 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a medication called to see if it can slow down cognitive decline—problems with thinking, memory, and daily functioning—in people who have early signs of thinking difficulties and two specific types of brain protein buildup (amyloid and alpha-synuclein). The medication works by targeting one of these problematic proteins. Researchers want to know if the treatment can help preserve thinking and memory abilities over 18 months.

Currently, there are limited treatment options for people experiencing early cognitive decline with these specific protein patterns in the brain. This trial is testing whether this medication can slow the progression of symptoms and help maintain quality of life in people at this early stage.

Do you qualify?

You likely qualify if…

you have experienced gradual cognitive decline (problems with thinking, memory, or concentration) for at least 6 months
you have at least one symptom typical of Lewy body dementia, such as visual hallucinations, movement problems, or sleep disturbances
you score 20 or higher on a standard memory and thinking assessment test
you have confirmed evidence of amyloid and alpha-synuclein protein buildup in your brain (detected through spinal fluid testing)
you have a trusted family member or close friend willing to participate as your study partner and monitor your well-being throughout the study

You likely don't qualify if…

you have a serious or unstable medical condition that could interfere with the study
you have another significant brain or neurological disease (besides your current condition) that could affect your thinking or ability to complete the study
you have a history of cancer with high risk of recurrence that could prevent you from finishing the trial
you have had a previous treatment specifically targeting amyloid protein in the brain
you cannot safely have an MRI scan, PET scan, or lumbar puncture (spinal tap)

What participation looks like

You would be randomly assigned to receive either the experimental medication or a placebo (inactive infusion) through an IV infusion over 18 months. During this time, you'll have regular clinic visits for infusions, cognitive testing to measure your thinking and memory, brain imaging scans, and spinal fluid testing. Your study partner will be involved in assessing how you're doing with daily activities. The study is designed to track whether the medication slows your cognitive decline compared to placebo.

AI-generated summary from trial data · Jun 25, 2026 · Not medical advice

Trial locations(72 sites)

United States

TrialSphere Corp, Chandler, Arizona

HonorHealth Research Institute, Scottsdale, Arizona

Profound Research LLC, Carlsbad, California

Irvine Clinical Research, Irvine, California

UCSD - Altman Clinical and Translational Research Institute (ACTRI), La Jolla, California